FDA Approved: EYLEA HD — Supplemental Application (Regeneron Pharmaceuticals, Inc)

View source ↗

Summary

FDA approved a supplemental application for EYLEA HD (aflibercept) from Regeneron, indicating a labeling change for the high-dose formulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Macular Edema Following Branch Retinal Vein Occlusion
• Macular Edema Following Central Retinal Vein Occlusion
• Wet Age-related Macular Degeneration

Drugs mentioned

• EYLEA HD (aflibercept)

Snippet

SUPPL AP for EYLEA HD (AFLIBERCEPT)